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ABSTRACT
Huntington Disease (HD) is an autosomal dominant neurodegenerative disease caused by an
expansion of a CAG trinucleotide repeat tract in the huntingtin (HTT) gene. This CAG tract
expansion causes production of mutant HTT (mtHTT) protein, which misfolds and forms
inclusions in the brain that accumulate with age. Misfolded mtHTT aggregates have been linked
with increased cell death in neuron cell culture, leading to speculation that mtHTT aggregates
cause cell death. However, there are mouse lines that have robust mtHTT inclusion deposition,
but no HD-like signs or neurodegeneration. Furthermore, neuronal HD cultured cells with
inclusions were found to be less likely to die compared to those with no inclusions. These
findings indicate that mtHTT inclusions may play a neuroprotective role in HD by sequestering a
toxic soluble form. Cell cultures show increased levels of stress response proteins when
oligomeric mtHTT levels are elevated, indicating that oligomers may be the toxic species driving
disease pathogenesis. Our lab has recently shown that inducing age-related changes in HD
neurons induces oligomer formation. This finding suggests that there is a potential link between
biological age and mtHTT misfolding. I am investigating this relationship by assessing mtHTT
aggregation in the brains of HD model mice that have undergone anti-aging therapy using EM48,
an antibody that recognizes misfolded mtHTT. The results of this study may provide further
insight into the relationship between biological age and accumulation of misfolded mtHTT
protein. If we find a relationship between biological age and mtHTT misfolding that can be
therapeutically modulated, this may provide new insight into the ‘toxic species’ of mtHTT and
would have implications for strategies aimed at reducing its levels. No effects of ‘young blood’
(YB) therapy were observed in this study. But due to limitations in the study, a conclusion on the
effect of YB treatment will require further work, including optimization of image processing and
processing of a greater number of animals.
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INTRODUCTION
HD is caused by an expanded CAG tract in the huntingtin (HTT) gene that codes for
mutant HTT (mtHTT) protein [1]. Wild type (WT) HTT protein performs several processes in
neurons which mtHTT protein disrupts, eventually leading to cell death [2]. HD patient brains
have an accumulation of mtHTT containing inclusions as disease progresses [3], but the
relationship between mtHTT misfolding and disease pathogenesis is still unclear.
Huntingtin protein misfolding has different states. Monomeric mtHTT protein is
aggregate prone and has several intermediate states of aggregation before forming an inclusion
body. Monomeric mtHTT assemble into larger masses of protein called oligomers. These
oligomers assemble into longer chains called proto-fibrils. The proto fibrils will join with other
proto-fibrils and larger oligomers to form the inclusion body [4].
Protein inclusion bodies are a part of many neurodegenerative diseases and are known to
hinder WT protein function by physically blocking and sequestering protein, preventing them
from performing normally. In fact, there is evidence that mtHTT protein aggregation is toxic to
cells. Rat cortical neurons transfected with exon 1 of mtHTT show robust inclusion formation
and cell death [5]. However, the exon 1 portion of the HTT gene is just a fragment of the full
protein and due to this being a transfection model, the mtHTT exon 1 is overexpressed. This
makes it hard to relate this to physiological protein function. It is also important to note that
while this study shows that mtHTT may cause death in rat cortical neurons, it does not show that
death is necessarily caused by mtHTT inclusions. Furthermore, mtHTT inclusions can be present
without disease. The YAC128 HD mouse model expresses a full length human mtHTT transgene
and shows neurodegeneration as well as behavioral phenotypes associated with HD [6]. There
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are two sub strains of YAC128 mice, however, that do not exhibit HD-like changes; YAC128
C6R mice that have a mtHTT protein that is resistant to caspase-6 cleavage and YAC128
shortstop mice have a premature stop codon which produces a shorter fragment of mtHTT [7, 8].
Both of these YAC128 strains have a mutation that makes the mtHTT protein non-pathogenic,
but in both cases the altered mtHTT is still aggregate prone, resulting in mice with robust brain
mtHTT inclusions in the absence of signs of disease. This shows that HD pathology may not be
driven by protein aggregation. In fact, there is even evidence that inclusion body formation may
be a neuroprotective response in HD. In striatal neurons transfected with mtHTT exon 1 it has
been found that that those with inclusion body formation, have reduced intracellular levels of
diffuse HTT and decreased risk of cell death [9]. Furthermore, an intrabody gene therapy that
prevents mtHTT aggregation by stabilizing soluble mtHTT was found to result in decreased
survival in an HD mouse model [10], suggesting that there may be a soluble, toxic species of
mtHTT, such as oligomers. In fact, there is some evidence that toxic mtHTT oligomers play a
causative role in progression of cell death. In a conditional inactivation model of mtHTT,
increase of endoplasmic reticulum stress response proteins from cultured striatal neurons
corelates with mtHTT oligomer formation [11], suggesting that the oligomers are what cause
cellular stress and toxicity. But while we have evidence for potential oligomeric toxicity, it is
important to understand what can modulate that aggregation. Biological age may be a modulator
considering that it has such a significant relationship with onset of HD.
HD is an adult-onset disease. This means that patients live for several decades without
displaying symptoms, but these same patients have mtHTT present in their bodies throughout
their lives. This indicates that aging may play a role in disease. In fact, there are many
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similarities between processes of biological aging and those of HD pathogenesis [12].
Furthermore, there is evidence for advanced biological age in HD brain tissue. DNA methylation
levels increase as you age, and postmortem HD brains have greater methylation levels compared
to WT brains of the same age [13], suggesting that HD brains are biologically older. Consistent
with this, our lab has recently shown that biological age may play a role in HD-related cellular
dysfunction. We induced age-related changes in HD neurons using progerin, a truncated form of
lamin A that causes Hutchinson-Gilford progeria syndrome, a disease of premature aging, and
observed HD-specific exacerbation of DNA damage as well as increased susceptibility to cellular
stress. Additionally, we observed aggregate seeding/oligomerization of mtHTT in progerin
treated neurons, (Figure 1) [14] suggesting that biological age may affect mtHTT misfolding.
Figure 1. Progerin treatment causes mtHTT
oligomerization in HD neurons [14]. Cultured
Hu97/18 primary cortical neurons were treated
with either nuclear GFP (nGFP) control (top) or
GFP-progerin (bottom), and EM48
immunocytochemistry was used to assess
mtHTT misfolding because EM48 only
recognizes misfolded or aggregated mtHTT. In
nGFP treated Hu97/18 neurons, no EM48
immunoreactivity is observed, demonstrating
that mtHTT is present only in soluble,
monomeric form. Conversely, inducing agerelated changes with progerin treatment
resulted in conversion of mtHTT to a form
recognized by EM48.
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The results of this study shows that age may worsen HD, and due to that, anti-aging
therapy may hold some merit as a potential treatment. So, our lab conducted an anti-aging
preclinical trial, and in this trial, we used the anti-aging therapy ‘young blood’. Young blood
treatment was chosen since it has been shown to improve cognitive performance, neurogenesis,
and synaptic plasticity in old mice [15]. For our preclinical trial we used the Q175FDN mouse
model of HD due to its robust, progressive deposition of inclusion bodies in brain [16].
Q175FDN heterozygous (Het) mice and wild-type (WT) littermates were given systematic
injections of young blood collected from young WT or Het mice starting at 6 months of age,
around the time of motor onset, until collection at 12 months of age when neuropathology is
known to be advanced (Figure 2). It is important to note that one of the main differences of Het
young blood is that it contains mtHTT species [17]. A previous study demonstrated that
Q175FDN homozygous (Hom) mice at 3 months of age show preferential deposition of
inclusions in the projection layers of the cortex, with fewer inclusions in layer IV. However, by
12 months, uniform cortical coverage of inclusions including layer IV is observed. Inclusion
deposition patterns were observed to be similar between 3-month-old Hom mice and 6-monthold Het mice [16], suggesting that the observed Hom inclusion deposition pattern is similar the
Het pattern at a delayed age. Considering that Het mice are more representative of human HD,
they were used in the trial.
In an effort to better understand the relationship between biological age and mtHTT
misfolding, I have assessed mtHTT aggregation in brains of mice treated with the anti-aging
therapy ‘young blood’. To provide a representation of the deposition of inclusion bodies during

4

natural aging, naïve Q175FDN mice at the age of treatment initiation and collection were also
evaluated.

Figure 2. Overview of young blood anti-aging trial in Q175FDN HD model mice

METHODS
Animals
Experiments were performed using Q175FDN [16] HD model mice and WT littermate
controls. Animals were maintained under a 12-hour (h) light:12 h dark cycle in a clean facility
and given ad libitum access to food and water. Approximately equal numbers of male and female
mice were used. For the anti-aging trial two genotypes were used, Q175FDN het and WT
littermates, each given one of three treatments, young blood from WT mice, young blood from
Q175FDN het mice, or saline control. Each of the 6 experimental groups had 15-16 mice. These
mice were divided into three cohorts of approximately equal number. For the naïve mouse study,
the 6-month-old Q175FDN group had 5 het and 4 WT mice and the 12-month-old Q175FDN
5

group had 4 het and 6 WT mice. Experiments were performed with the approval of the
Institutional Animal Care and Use Committee at the University of Central Florida (2020-35).

Tissue Collection and Processing
Naïve 6- and 12-month-old mice were anesthetized using 2,2,2-Tribromoethanol
(Avertin, Sigma Aldrich, catalog # T48402) and transcardially perfused with PBS containing 10
IU/mL heparin followed by 4% paraformaldehyde (PFA) in PBS. Mouse brains were removed
and post-fixed in 4% PFA in PBS for 24 hours at 4°C. The following day, brains were
transferred into 30% sucrose containing 0.01% NaN3. Once equilibrated, typically taking around
24 hours, brains were rapidly frozen in Tissue-TEK O.C.T. embedding compound (Sakura,
catalog # 4583) using a dry ice ethanol slurry, and cut via cryostat (Leica CM3050S) into 25 μm
free-floating coronal sections in PBS with 0.01% NaN3. Sections were collected in a series of 8
wells, so that each well contains a series of sections spaced 200 μm apart that spans the striatum.
While cutting, the wells containing the sections where the corpus callosum and the anterior
commissure cross, connecting the hemispheres, were marked.

mtHTT Immunohistochemistry
To assess mtHTT, I used EM48 immunoreactivity. EM48 is an antibody recognizing an
epitope in exon 1 of HTT that is more exposed in the mutant form. Thus, EM48 selectively binds
to misfolded mtHTT. Sections from 2 wells after the corpus callosum connection were used for
analysis. Sections were washed 3x10 minutes in PBST (PBS with 0.03% Triton-X100) and
quenched in 3% hydrogen peroxide, 10% methanol PBST solution for 30 minutes at room
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temperature to exhaust endogenous peroxidases that could confound results, after which they
were washed 3x10 minutes in PBST. Sections were then blocked in 5% NGS, 5% BSA, 0.2%
TritonX-100 PBS solution for 1 hour. Sections were incubated in EM48 moue anti-misfolded
HTT (1:100, Millipore MAB5374) primary antibody overnight at 4oC. Sections were washed
3x10 minutes in PBST and incubated in goat anti-mouse biotinylated secondary antibody (1:500,
Vector) for 2 hours at room temperature followed by a wash in 3x10 minutes in PBST and
incubation in ABC reagent (Vector Laboratories PK-6101). The ABC reagent contains avidin
which binds to the biotin from the biotinylated secondary antibody, forming an enzyme complex.
Following the ABC reagent incubation, sections are washed in 3x10 minutes in PBST and then
stained with metal enhanced DAB substrate (Thermo Scientific 34065) for 1 minute. DAB
substrate associates to the ABC/secondary antibody enzyme complex to form the colored stain.
Sections were then floated in PBS before being mounted on slides, using a paintbrush to gently
maneuver them. Sections were arranged on slides in columns of three with the most anterior
section positioned in the top left and most posterior section positioned at bottom right. Each
mouse used one slide. Slides were then air dried, and coverslipped with permount mounting
medium (Fisher SP15-500). The cover slipped sections were imaged using brightfield
microscopy (Keyence BZ-X810) at 20X magnification. Images of layer IV of the primary
somatosensory cortex were taken in both the left and right hemispheres of the 4 sections anterior
to the anterior commissure connection in each series, for a total of 8 images per brain.
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Image Processing
The mtHTT inclusions were quantified by measuring integrated optical density (IOD) of
EM48 immunoreactivity and percent of the total area covered by staining. Images were
processed using ImageJ (version 1.53k, NIH). The region of interest (ROI), layer IV, was traced
using the polygon selection tool. The images were converted to black and white and detection
threshold was adjusted to only pick up the dark inclusions. Measurements were set to quantify
total area, minimum and maximum gray value, IOD, area fraction and mean gray value.
Detection was limited to the selected upper threshold. Brains that were not properly perfused
may contain sections with nonspecific secondary antibody binding due to the endogenous mouse
antibodies in the residual blood, which would be detected by the anti-mouse secondary used in
this study. This non-specific staining would result in inflated measurements for these sections,
thus they were excluded from analysis. Treatment type was blinded to prevent bias during
thresholding and tracing. The mean value of the area fractions and the IOD were calculated per
brain. Only Het brains were analyzed in this described manner. WT brains were qualitatively
analyzed to determine a lack of EM48 immunoreactivity.

Statistical Analysis
Naïve mouse data was analyzed by unpaired two-tailed t test to compare staining for 6
and 12 months followed by Dunnet’s post hoc test. Survival was tracked over the course of the
preclinical trial and analyzed by Log-rank Mantel Cox test. Trial data was analyzed by 2-way
analysis of variance (ANOVA) for sex and treatment and Sidak post-hoc analysis. Treatment
group data was analyzed by 1-way ANOVA for treatment and Dunnett post-hoc analysis.
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RESULTS
Survival of saline injected Het males was significantly reduced.
Previous analysis of survival rates of the Q175FDN mouse line shows reduced survival in
Het mice compared to WT littermates from 12 months of age[16]. Conversely, The anti-aging
preclinical trial induced significantly reduced survival in saline injected Het male mice from 9
months of age (Figure 3). As a result, only 1 saline treated Het male mouse was included in this
neuropathological study. There was no effect of genotype or treatment on survival of female
mice (data not shown).

Figure 3. Reduced survival of saline treated Q175FDN males was observed in anti-aging preclinical trial.
Q175FDN Het mice were aged to 6 months after which they were given 3x weekly systemic injections with saline,
WT young blood, or Het young blood until 12 months of age, when they were collected. Reduced survival of saline
treated Het males was observed over the course of those 6 months, which is earlier than the previously studied rates

9

of survival in this mouse line. N=9 WT saline, N=7 WT WT YB, N=8 WT Het YB, N=6 Het saline, N=7 Het WT
YB, N=8 Het Het YB, Log rank Mantel-Cox test, ** = p < 0.01.

Figure 4. High magnification images of sections that were not quantitatively analyzed. (A) mtHTT inclusions
and residual blood inside blood vessels are able to be differentiated by qualitative shape analysis. The inclusions are
punctate DAB staining while the vessels are long strands of DAB stain caused by non-specific secondary antibody
binding to endogenous mouse antibodies. The long strands can cause the measurements to inflate. (B) WT brains do
not have any mtHTT immunoreactivity, making the previously described quantitative analysis insignificant as a
proper measuring tool.
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Q175FDN Het mice show progressive mtHTT inclusion deposition
A previous study showed that Q175FDN Hom mice show preferential deposition of
inclusions in the projection layers of the cortex by 3 months of age, with fewer inclusions in
layer IV. However, by 6 and 9 months, progressive cortical coverage of inclusions including
layer IV was observed. [16]. Considering that these mice were homozygous for the HD mutation,
as opposed to the Het mice used in our study, a more rapid progression of inclusion deposition in
the Hom mice is expected. Thus, we expect 6-month Het mice to be similar to the previous
report about 3-month Hom mice. This is consistent with what was seen in this study; however,
we also observed preferences in mtHTT inclusion deposition among different regions of the
cortex. Looking back at the published images from the previous study, the timeline for Hom
deposition patterns show the same thing, although it wasn’t previously remarked upon. In the
primary motor cortex, the cortical region earliest affected in HD, there were already a large
number of inclusions in layer IV at 6 months of age. But, at that same timepoint, we saw
significantly less deposition in areas less affected by HD, such as layer IV of the primary
somatosensory cortex. By 12 months, we observed uniform cortical coverage of inclusions
including layer IV of the primary somatosensory cortex. Quantitative analysis of somatosensory
cortex layer IV images revealed similar results. At 12 months of age naïve mice displayed
increased percent EM48 positive area (Figure 5A, p = 0.0136.) and increased EM48 IOD (Figure
5B, p = 0.0359.).
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Figure 5. Age dependent increase of area fraction and IOD was observed in naïve Q175FDN Het
somatosensory cortex layer IV. Naïve Q175FDN Het mice were aged to either 6 or 12 months of age and collected
for brain mtHTT immunohistochemistry (EM48). We observed a significant age-dependent increase in both layer IV
EM48 (A) area fraction and (B) IOD. N=3, Student’s t-test, * = p < 0.05.

No effect of Young blood treatment was observed on mtHTT inclusion deposition
To evaluate the effect of young blood anti-aging therapy on mtHTT misfolding, we
compared young blood treated Q175FDN Het mice with saline treated mice. 2-way ANOVA for
sex and treatment and Sidak post-hoc analysis showed no significant effect of sex in both area
fraction (Figure 6A, p = 0.7801) and IOD (Figure 6B, p = 0. 9352), respectively, so sexes were
combined for subsequent analysis. 1-way ANOVA showed no significant effect of treatment in
both area fraction (Figure 6C, p = 0.4150) and IOD (Figure 6D, p = 0.7801), respectively.
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Dunnett’s post hoc analysis further confirmed a lack of treatment effect (saline vs WT YB
p=0.3998, saline vs Het YB p=0.4058).
To evaluate the effect of HD on anti-aging therapy we compared WT young blood
treated Q175FDN mice with Het young blood treated Q175FDN mice and did not see a
difference (Dunnet’s post hoc test WT YB vs Het YB p=0.9776).

Figure 6. No effect of sex or treatment was observed for somatosensory cortical layer IV inclusion deposition.
Q175FDN Het mice were treated with saline, WT YB or Het YB from 6 months of age until they were collected at
12 months of age for brain mtHTT immunohistochemistry (EM48). No differences between the sexes were observed
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in both (A) area fraction (2-way ANOVA, p = 0.7801) and (B) IOD (2-way ANOVA, p = 0.9352). No significant
difference was observed among groups after sexes were pooled into treatment groups in both (C) area fraction (1way ANOVA, p = 0.4150) and (D) IOD (1-way ANOVA, p = 0.7801. N=5 for saline (1M/4F), N=5 for WT YB
(2M/3F), N=6 for Het YB (4M/2F)

Discussion
In this study, the effects of anti-aging therapy ‘young blood’ on mtHTT inclusion body
deposition in the brains of HD model mice and the effects of the HD mutation on young blood
therapy were evaluated. Both of these were investigated in efforts to better understand the
relationship between biological age and mtHTT misfolding.
In the anti-aging preclinical trial, a significant loss of saline injected male Q175FDN Het
mice was observed. This could be due to the stress of going through a preclinical trial causing
changes in the mice. The key reason this is highlighted is because in the original study that
observed no significant drop in survival until post 12 months, the mice did not undergo 3x
weekly injections. In the anti-aging preclinical trial however, the saline injected mice
experienced intravenous injections 3 times a week. This additional stress may have changed the
mice. WT HTT is a stress response protein, and in HD, stress resistance is altered, so any sort of
stress may have increased effects in the mice [14]. The reason only the saline treated mice died
could be explained by the fact that the other mice were receiving a potential therapeutic agent in
the form of YB.
In the naïve Q175FDN study, we observed preferential deposition of inclusions in the
primary motor cortex by 6 months of age compared to the somatosensory cortex, which has a
relative lack of inclusions in the non-projection layers. By 12 months, however, the inclusion

14

deposition is uniformly distributed across all regions of the cortex. This is similar to the
previously observed inclusion deposition patterns in the somatosensory cortical layers. In fact,
the deposition patterns in the cortical layers follow a previously observed trend in neuronal loss
observed in the YAC128 HD model mouse [18]. The primary motor cortex, which shows
increased thinning and neuronal loss, is also the region that shows preferential deposition of
inclusion bodies in Q175FDN brain. In contrast, there is no projection layer thinning in the
somatosensory cortex of YAC128 mice [19]. Observing that the cortical layers that show greatest
thinning and neuronal loss, also have the most deposition of inclusion bodies, we have shown
that the areas more affected by HD will also show greater deposition of mtHTT inclusions.
In the anti-aging preclinical trial, we observed no significant difference between saline
treatment and YB treatments as well as no significant difference between YB WT and YB Het
treatments. While we observe no difference between the treatment types, the values for area
fraction and IOD both are similar to the values found in the 12-month-old naïve mice. This
suggests that the saline treatment preserved “normal” conditions for the mice and that the
treatment regimen alone did not alter inclusion deposition. One other thing to note is the large
amount of variability in the preclinical trial image measurements compared to the naïve brains.
This may have been due to inconsistencies during thresholding. The processes behind selecting
the region of interest and the threshold with which to measure the area fraction and IOD is
subjective due to the lack of strict boundaries. It is difficult to make the measurements consistent
since the threshold is set by human preference. These limitations to the current image analysis
methods may cause varied or skewed data. A potential solution to this issue would be to strictly
follow a set of boundaries based on stable colors in the image, such as an inclusion. Another
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solution could be to adjust the lower threshold to exclude all of the background staining. In
future work, I will employ these techniques to attempt to reduce variability in analysis.
The ‘young blood’ treatment used in this study served two roles. To investigate potential
benefits of anti-aging on mtHTT misfolding and to investigate the effects of HD on the
rejuvenating potential of young blood treatment. The reason for this is that WT young blood on
its own introduces too many factors. Another study showed an improvement in pathological
symptoms of HD mice when exposed to WT blood of the same age via parabiosis [20],
demonstrating the presence of ‘toxic’ factors in HD circulation. So, we would not be able to
differentiate the effects of the treatment as young blood providing benefit to old mice or as WT
blood benefiting HD mice. Even with this differentiation being tested, it is not perfect. HD young
blood may not be as young as the WT young blood. Circulatory telomeres from HD patients are
shorter compared to non-HD circulatory telomeres, indicating that the accelerated aging aspect
of HD is not limited to the brain [21]. Thus, the young blood derived from HD mice may contain
factors associated with older age. Because of this, the presence of mtHTT may not be the only
difference between the WT and HD young blood.
However, even if there is a benefit found in young blood, there is still a problem with it
as a feasible therapy for HD patients. There is simply not enough young blood in the world to
viably be used for treatment. Recently, a study used saline to replace the aged mouse blood
plasma by resuspending isolated red blood cells and mouse albumin in saline solution before
injecting into aged mouse circulation. While injecting the saline solution, the mouse was also
bled, resulting in an exchange of blood effectively only replacing the blood plasma with saline.
The study showed similar rejuvenation to young blood treatment providing evidence that
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rejuvenation from young blood may not be caused by an exposure to young systemic factors, but
rather a decrease in old systemic factors [22]. This finding may provide a potential solution to
the supply issues present with young blood. This study, paired with the previously mentioned
study on the benefits to HD mice given WT blood, show that there may be systemic factors to
HD that play a role in disease pathogenesis, further suggesting a potential benefit of saline
plasma exchange to HD, beyond rejuvenation.
Overall, quantitative analysis showed no difference in inclusion deposition pattern
between young blood treated and 12-month naïve Q175FDN mice and we observed no
significant effect of anti-aging therapy on mtHTT inclusion deposition in the brains of Q175FDN
het mice. However, considering the variability observed in the trial mouse brains, it will be
impossible to draw conclusions about the effect of young blood therapy until completion of
ongoing work, including optimization of the quantitative technique as well as processing a
greater number of brains.
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